Table 1

Studies of romidepsin as a single agent for treating mature T-cell lymphomas.

Studies	Setting	Study design	N	PTCL subtypes	Median N of prior therapies	ORR	CR rate	PFS	Median duration of response
Coiffeir et al. [5, 7]	RR	Phase 2, multicenter	130	PTCL NOS (N=69, 53%)	2 (1–8)	25%	15%	4 mo	28 (1–48+) mo
Coiffeir et al. [5, 7]	PTCL			AITL (N=27, 21%)
Piekarz et al. [8]	RR	Phase 2, multicenter	47	PTCL NOS (N=27, 59%)	3 (1–11)	38%	18%	8.9 mo	8.9 (2–74) mo
Piekarz et al. [8]	PTCL			AITL (N=7, 15%)
Maruyama et al. [9]	RR	Phase 1/2 multicenter	50	PTCL NOS (N=20, 42%)	7.1 (1.2–82.9)	44%	23%	5.6 mo	11.1 mo
	PTCL			AITL (N=21, 44%)
	CTCL

Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; CR, complete response; ORR, overall response rate; PFS, progression-free survival; PTCL NOS, peripheral T-cell lymphoma not otherwise specified; RR PTCL, relapsed and refractory PTCL.

Blood Res 2020;55:175~177 https://doi.org/10.5045/br.2020.2020045